A Comparison of Tumor Biology in Primary Ductal Carcinoma In Situ Recurring as Invasive Carcinoma versus a New In Situ
Table 2
Molecular characteristics among women with a primary DCIS who later developed either an invasive cancer or an in situ recurrence. Women with a known recurrence were recruited from two source populations: a population based cohort (U/V cohort, ) and a randomized study (SweDCIS, 1,046).
Molecular Characteristics of primary DCIS
All DCIS with a recurrence ()
U/V cohort () Type of recurrence
SweDCIS () Type of recurrence
All DCIS with a recurrence () Type of recurrence
Invasive () Number
In situ () Number
Invasive () Number
In situ () Number
Invasive () Number (%)
In situ () Number (%)
ER ()
Positive
38
27
36
32
74 (81.3)
59 (65.5)
Negative
10
16
7
15
17 (18.7)
31 (34.5)
PR ()
Positive
25
20
28
24
53 (55.8)
44 (50.0)
Negative
26
22
16
22
42 (44.2)
44 (50.0)
HER2 ()
Positive
15
18
13
22
28 (30.4)
40 (47.1)
Negative
37
24
27
21
64 (69.6)
45 (52.9)
EGFR ()
Positive
10
16
14
19
24 (32.0)
35 (51.5)
Negative
33
18
18
15
51 (68.0)
33 (48.5)
CK5/6 ()
Positive
42
32
40
46
82 (94.3)
78 (94.0)
Negative
3
4
2
1
5 (5.7)
5 (6.0)
KI67 ()
High
15
11
13
16
28 (37.3)
27 (38.0)
Low
32
25
15
19
47 (62.7)
44 (62.0)
Subgroups based on IHC ()
ER+/HER2−
10
6
8
9
51 (37.5)
36 (28.0)
ER+/HER2+
28
19
23
17
18 (13.2)
15 (11.5)
ER−/HER2+
4
11
4
10
8 (5.9)
21 (16.2)
**ER−/HER2−/CK+ or EFGR+
3
5
3
3
6 (4.4)
8 (6.2)
Unknown
10
4
43
46
53 (39.0)
58 (44.6)
We used the classification for basal-like DCIS published by Livasy et al., 2007 [22], and also used in an earlier paper by us [37].
